Amanda's husband seemed able to read her mind. Then she learnt why - ABC News & Headlines – Australian Broadcasting Corporation

Give someone a car brand and ask them to name a car from that brand, and you’ll probably get some highly expected answers. Ford probably gets you F-150, Mustang, and Bronco. Toyota will likely hit the button for Camry, Corolla, and RAV4. Cadillac might tap Eldorado, DeVille, and Blackwing. But Cimarron? Unlikely (at least for normies, as opposed to, you know, us.) It’s not unusual for brands to have models that are seemingly so far astray from what the nameplate represents that you probably wonder how they ever got built.

The investigational factor XI (FXI) monoclonal antibodies amrecibart and cenvacibart demonstrated successful anticoagulation with a favorable safety profile in preclinical and phase 1 clinical studies, representing a novel treatment strategy for patients with thrombosis. The results were published in Blood by Dan Chalothorn, PhD, of Regeneron Pharmaceuticals, and colleagues. The research team first compared the mechanisms and coagulation effects of amrecibart and cenvacibart with other FXI-targeted monoclonal antibodies in both human and nonhuman primate plasma using an in vitro functional clotting assay.1Targeting the Intrinsic PathwayWith unique FXI/FXIa-binding mechanisms, amrecibart and cenvacibart address an unmet need for novel treatments with a favorable risk-benefit profile because current standard-of-care anticoagulants carry a high risk for bleeding. Cenvacibart and amrecibart block FXI activity by targeting the catalytic domain and the apple 2 domain of FXI/FXIa, respectively. Although standard-of-care anticoagulants target the extrinsic coagulation pathway, these monoclonal antibodies specifically target the intrinsic coagulation pathway.